Aberdeen Group
PRQR icon

Aberdeen Group’s ProQR Therapeutics PRQR Stock Holding History

Aberdeen Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
8,932,507
+5,615,542
+169% +$9.25M 0.02% 491
2026
Q1 		$5.37M Buy
3,316,965
+366,289
+12% +$600K 0.01% 681
2025
Q4 		$5.96M Buy
2,950,676
+651,853
+28% +$1.52M 0.01% 678
2025
Q3 		$4.9M Buy
2,298,823
+448,475
+24% +$980K 0.01% 700
2025
Q2 		$3.77M Hold
1,850,348
– – 0.01% 732
2025
Q1 		$2.46M Buy
+1,850,348
New +$3.94M ﹤0.01% 745

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Aberdeen Group's PRQR Position: Q2 2026 in Review

Aberdeen Group increased its ProQR Therapeutics (PRQR) stake by 169% in Q2 2026, buying an estimated $9.25M and bringing the position to 8,932,507 shares worth $16.6M. The position accounts for 0.02% of the portfolio, ranked #491.

Aberdeen Group first reported a position in PRQR in Q1 2025 and has held it in 6 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Aberdeen Group held 8,932,507 shares of ProQR Therapeutics worth $16.6M as of Q2 2026.
  • Aberdeen Group bought 5,615,542 ProQR Therapeutics shares in Q2 2026, an estimated $9.25M.
  • ProQR Therapeutics made up 0.02% of Aberdeen Group's portfolio in Q2 2026, its #491 holding.
  • Aberdeen Group first reported a position in ProQR Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.